Joslin Diabetes Center is the world’s largest diabetes research center, diabetes clinic, and provider of diabetes education. It is located in the Longwood Medical and Academic Area in Boston, Massachusetts, USA. Among the Harvard Medical School Affiliated institutions, Joslin is unique in its sole focus on diabetes. Joslin has the world’s largest team of board-certified physicians treating diabetes and its complications, as well as the largest staff of Certified Diabetes Educators anywhere in the world.Since its inception, Joslin has focused on aggressive, comprehensive care of the patient. Over 23,000 active patients receive specialty care for their eyes, hearts, kidneys, pregnancies and feet.Joslin supports the world’s largest diabetes research team with more than 40 faculty level investigators for a total of more than 300 researchers.Joslin has 46 clinical care affiliates in the US and two in other countries. Wikipedia.
Agency: Department of Health and Human Services | Branch: | Program: STTR | Phase: Phase I | Award Amount: 150.00K | Year: 2014
DESCRIPTION (provided by applicant): Type 2 diabetes (T2D) has reached epidemic proportions in the United States, affecting an estimated 8.3% of the population. Unfortunately, the majority of individuals with diabetes continue to have suboptimal control ofglucose, therefore new and improved approaches to prevention and treatment are sorely needed. Dr. Mary Elizabeth Patti's laboratory at the Joslin Diabetes Center (JDC) has recently identified a novel pattern of gene expression in skeletal muscle from human patients with established T2D. This pattern includes increased expression of genes regulated by serum response factor (SRF) and its upstream regulatory protein STARS (striated muscle activator of Rho-dependent signaling). Importantly, this pattern is also present in those at risk for disease based on family history, potentially linking this to T2D-risk. Genetic and pharmacologic data from the Patti lab (JDC) robustly indicate that modulation of the STARS-SRF pathway can regulate muscle insulin resist
Brigham, Women's Hospital and Joslin Diabetes Center | Date: 2014-02-14
Methods for regenerating thymic tissues, e.g., for the treatment of subjects who have thymic insufficiency, i.e., whose thymic tissues are absent or atrophied due to illness, age, or injury, by administration of growth differentiation factor 11 (GDF11).
Joslin Diabetes Center and Sanofi S.A. | Date: 2014-02-21
Compositions and methods of use are provided for improving cell function and promoting pancreatic cell proliferation in vitro, in vivo and ex vivo. The active agents of the pending invention comprise Serpin family peptides (e.g., SerpinB1), functional and structural analogs of Serpin family peptides and nucleic acids encoding Serpin family peptides, as well as active fragments thereof.
Aiello L.P.,Joslin Diabetes Center
Diabetes Care | Year: 2014
Objective To evaluate whether intensive treatment (INT) with the goal of achieving blood glucose levels as close to the nondiabetic range as safely possible reduced the risk of onset and progression of diabetic retinopathy (DR) in subjects with type 1 diabetes (T1D) compared with conventional therapy (CON). Research Design And Methods The Diabetes Control and Complications Trial (DCCT) (1982-1993) was a multicenter, controlled clinical trial comparing INT with CON for onset and progression of DR. The Epidemiology of Diabetes Interventions and Complications (EDIC) study (1994-present) is an observational follow-up of the DCCT cohort. Results Of the 1,441 DCCT subjects, 726 had no DR (primary prevention cohort) and 715 had mild DR (secondary intervention cohort) at baseline. Subjects were followed for a mean of 6.5 years. INT median HbA1c was 7% compared with CON median of 9%. INT reduced the adjusted mean risk for the development of DR by 76% and slowed progression of DR by 54% compared with CON. Following DCCT, the HbA1c levels in the original INT and CON groups converged (year 8, INT 7.98%; CON 8.07%); nevertheless, the groups continued to have a durable effect of initial assigned therapy with significantly lower incidence of further DR progression in the INT group (hazard reduction 53-56%). Severe retinal outcomes and procedures to treat them were reduced by 50% in the original INT group. Conclusions INT delays the onset and slows the progression of DR. Furthermore, the early effects of metabolic control continue to accrue over many years despite subsequent comparable glycemic control (metabolic memory). These results emphasize the need for optimizing glycemic control as early as possible in patients with diabetes. © 2014 by the American Diabetes Association.
Stanton R.C.,Joslin Diabetes Center
American Journal of Kidney Diseases | Year: 2014
Diabetic kidney disease (DKD) is a major and increasing worldwide public health issue. There is a great need for implementing treatments that either prevent or significantly slow the progression of DKD. Although there have been significant improvements in management, the increasing numbers of patients with DKD illustrate that current management is not wholly adequate. The reasons for suboptimal management include the lack of early diagnosis, lack of aggressive interventions, and lack of understanding about which interventions are most successful. There are a number of challenges and controversies regarding the current management of patients with DKD. Understanding of these issues is needed in order to provide the best care to patients with DKD. This article describes some of the clinically important challenges associated with DKD: the current epidemiology and cost burden and the role of biopsy in the diagnosis of DKD. Treatment controversies regarding current pharmacologic and nonpharmacologic approaches are reviewed and recommendations based on the published literature are made. © 2014 by the National Kidney Foundation, Inc.
Rask-Madsen C.,Joslin Diabetes Center |
King G.L.,Joslin Diabetes Center
Cell Metabolism | Year: 2013
In patients with diabetes, atherosclerosis is the main reason for impaired life expectancy, and diabetic nephropathy and retinopathy are the largest contributors to end-stage renal disease and blindness, respectively. An improved therapeutic approach to combat diabetic vascular complications might include blocking mechanisms of injury as well as promoting protective or regenerating factors, for example by enhancing the action of insulin-regulated genes in endothelial cells, promoting gene programs leading to induction of antioxidant or anti-inflammatory factors, or improving the sensitivity to vascular cell survival factors. Such strategies could help prevent complications despite suboptimal metabolic control. © 2013 Elsevier Inc.
Joslin Diabetes Center | Date: 2015-11-11
Described are methods of improving insulin sensitivity, and treating fatty liver disease (including non-alcoholic steatohepatitis (NASH)), by administering specific inhibitors of PKC delta.
Joslin Diabetes Center | Date: 2014-03-12
Provided herein are, for example, methods of diagnosing and/or treating inflammatory cardiomyopathy and/or post-myocardial injury autoimmunity. Such therapies involve suppressing an immune response to the alpha isoform of myosin heavy chain in the subject. In some embodiments, this suppression is done selectively.
Joslin Diabetes Center | Date: 2014-03-04
The present invention is related to methods and compositions effective in regulating glycemic control in subject individuals in need of the regulation of glycemic control. Said individuals may have diabetes or be prediabetic condition receive therapeutically effective amounts of identified secreted proteins in an amount suitable for modulating glycemic control and to thereby treat or prevent diabetes in said subject.
Joslin Diabetes Center | Date: 2014-06-13
This invention reveals a novel miRNA and a novel miRNA-regulated signaling network which controls brown adipogenesis and thermogenic programs, thereby providing a powerful approach for the treatment of obesity and related metabolic diseases. In this regard, the present invention is also directed towards methods of treatment of obesity and excess weight (overweight) and metabolic disorders caused by or aggravated by a subject being overweight or obese.